Muhammad Adnan Qamar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Adnan Qamar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Sarum Ali Khan
Wah Medical College, Wah Cantt, Pakistan
8 shared publications - Taimoor Ali
Wah Medical College, Wah Cantt, Pakistan
6 shared publications - Aiman Tahir
Department of Medicine, Azad Jammu and Kashmir Medical College, Muzaffarabad, AJK, Pakistan
5 shared publications - Aneeza Hameed
Wah Medical College, Wah Cantt, Pakistan
2 shared publications - Afnan Ahmad Qureshi
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication - Ailiya Batool
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4763-4764
Gene silencing versus protein stabilization in transthyretin amyloid cardiomyopathy: contextualizing the HELIOS-B results and the road to precision agent selection
Transthyretin amyloid cardiomyopathy (ATTR-CM) now has three approved disease-modifying agents: tafamidis, acoramidis, and vutrisiran, representing two mechanistically distinct classes: TTR tetramer stabilizers and RNA interference (RNAi) gene silencers. The phase 3 HELIOS-B trial, published in the New England Journal of Medicine, demonstrated that vutrisiran, a subcutaneous RNAi therapeutic, reduced the composite of all-cause mortality and recurrent cardiovascular events compared with placebo (hazard ratio 0.72; P = 0.01) in 655 patients with ATTR-CM over 33–36 months. These results supported the March 2025 FDA approval of vutrisiran for this indication. This letter contextualizes the mechanistic shift from stabilization to silencing, discusses the limitations of the HELIOS-B trial design, and examines the implications of an expanding therapeutic landscape for which patient-level selection criteria remain undefined. The ongoing CARDIO-TTRansform trial of the antisense oligonucleotide eplontersen will provide further comparative data, but head-to-head evidence across existing approved agents is absent. The question of how to sequence or select between mechanistically distinct agents for individual patients represents the central unresolved issue in ATTR-CM management.
- 9 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4763-4764
Open AccessGene silencing versus protein stabilization in transthyretin amyloid cardiomyopathy: contextualizing the HELIOS-B results and the road to precision agent selection
Transthyretin amyloid cardiomyopathy (ATTR-CM) now has three approved disease-modifying agents: tafamidis, acoramidis, and vutrisiran, representing two mechanistically distinct classes: TTR tetramer stabilizers and RNA interference (RNAi) gene silencers. The phase 3 HELIOS-B trial, published in the New England Journal of Medicine, demonstrated that vutrisiran, a subcutaneous RNAi therapeutic, reduced the composite of all-cause mortality and recurrent cardiovascular events compared with placebo (hazard ratio 0.72; P = 0.01) in 655 patients with ATTR-CM over 33–36 months. These results supported the March 2025 FDA approval of vutrisiran for this indication. This letter contextualizes the mechanistic shift from stabilization to silencing, discusses the limitations of the HELIOS-B trial design, and examines the implications of an expanding therapeutic landscape for which patient-level selection criteria remain undefined. The ongoing CARDIO-TTRansform trial of the antisense oligonucleotide eplontersen will provide further comparative data, but head-to-head evidence across existing approved agents is absent. The question of how to sequence or select between mechanistically distinct agents for individual patients represents the central unresolved issue in ATTR-CM management.
- Open Access
- 14 May 2026
- Vol. 88 (6) , 3909-3910
Exosome-based therapeutics: emerging extracellular vesicle platforms for targeted delivery in inherited retinal dystrophies and beyond
- 14 May 2026
- Vol. 88 (6) , 3909-3910
Open AccessExosome-based therapeutics: emerging extracellular vesicle platforms for targeted delivery in inherited retinal dystrophies and beyond
- Open Access
- 14 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3893-3894
IoMT-enabled implant sensors for early detection of neurovascular complications in craniofacial distraction osteogenesis
Craniofacial distraction osteogenesis (DO) is an established surgical technique for correcting complex craniofacial deformities and managing upper airway obstruction. Neurovascular complications, including injury to the inferior alveolar, infraorbital, and facial nerves, are recognized risks of the procedure. Current postoperative surveillance depends on periodic clinical examination and interval imaging, neither of which provides continuous insight into the mechanical forces transmitted to adjacent neurovascular structures during the active distraction phase. This letter examines whether implantable sensor technologies integrated with Internet of Medical Things (IoMT) infrastructure could address this monitoring gap. Micro-sensors capable of monitoring strain, pressure, and temperature at the tissue–implant interface have been demonstrated in musculoskeletal applications and are technically transferable to craniofacial distraction hardware. Continuous strain monitoring could detect abnormal force accumulation along the distraction vector before neurovascular injury thresholds are reached. Closed-loop feedback architectures could further allow dynamic modulation of distraction parameters in response to real-time physiological signals, reducing reliance on fixed-schedule activations that do not account for individual tissue response. No clinical studies have yet evaluated IoMT sensor integration in craniofacial DO, and significant barriers remain, including sensor biocompatibility, device miniaturization for pediatric use, wireless signal transmission through bone, and data security. Prospective feasibility studies are required before this approach can be considered for clinical implementation.
- 14 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3893-3894
Open AccessIoMT-enabled implant sensors for early detection of neurovascular complications in craniofacial distraction osteogenesis
Craniofacial distraction osteogenesis (DO) is an established surgical technique for correcting complex craniofacial deformities and managing upper airway obstruction. Neurovascular complications, including injury to the inferior alveolar, infraorbital, and facial nerves, are recognized risks of the procedure. Current postoperative surveillance depends on periodic clinical examination and interval imaging, neither of which provides continuous insight into the mechanical forces transmitted to adjacent neurovascular structures during the active distraction phase. This letter examines whether implantable sensor technologies integrated with Internet of Medical Things (IoMT) infrastructure could address this monitoring gap. Micro-sensors capable of monitoring strain, pressure, and temperature at the tissue–implant interface have been demonstrated in musculoskeletal applications and are technically transferable to craniofacial distraction hardware. Continuous strain monitoring could detect abnormal force accumulation along the distraction vector before neurovascular injury thresholds are reached. Closed-loop feedback architectures could further allow dynamic modulation of distraction parameters in response to real-time physiological signals, reducing reliance on fixed-schedule activations that do not account for individual tissue response. No clinical studies have yet evaluated IoMT sensor integration in craniofacial DO, and significant barriers remain, including sensor biocompatibility, device miniaturization for pediatric use, wireless signal transmission through bone, and data security. Prospective feasibility studies are required before this approach can be considered for clinical implementation.
- Open Access
- 28 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3874-3875
Ferroptosis at the crossroads of epilepsy and neurodegeneration
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a potential contributor to neuronal injury across neurological disorders. Increasing evidence suggests that ferroptotic mechanisms may participate in the pathophysiology of epilepsy, linking sustained oxidative stress, iron dysregulation, and progressive neuronal loss. Mechanistically, ferroptosis is driven by disruption of the canonical system Xc − –glutathione–glutathione peroxidase 4 axis, resulting in impaired detoxification of lipid hydroperoxides and membrane damage accumulation. Neurons are particularly susceptible due to high oxygen consumption, abundant polyunsaturated fatty acids, and vulnerability to iron-catalyzed reactive oxygen species generation. Experimental studies and gene expression analyses have identified ferroptosis-related pathways enriched in epileptic tissue, while human biomarker investigations demonstrate reduced glutathione levels and elevated lipid peroxidation products in patients with epilepsy. Although most therapeutic data derive from preclinical rodent models, pharmacological modulation of ferroptosis – via iron chelation or inhibition of lipid peroxidation – has shown seizure-reducing and neuroprotective effects. Importantly, ferroptosis likely operates alongside other regulated cell death pathways rather than acting as a singular mechanism. Shared features of iron accumulation and lipid peroxidation in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, further support a broader pathogenic relevance. Continued translational investigation is necessary to determine whether targeting ferroptosis may offer disease-modifying strategies in epilepsy.
- 28 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3874-3875
Open AccessFerroptosis at the crossroads of epilepsy and neurodegeneration
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a potential contributor to neuronal injury across neurological disorders. Increasing evidence suggests that ferroptotic mechanisms may participate in the pathophysiology of epilepsy, linking sustained oxidative stress, iron dysregulation, and progressive neuronal loss. Mechanistically, ferroptosis is driven by disruption of the canonical system Xc − –glutathione–glutathione peroxidase 4 axis, resulting in impaired detoxification of lipid hydroperoxides and membrane damage accumulation. Neurons are particularly susceptible due to high oxygen consumption, abundant polyunsaturated fatty acids, and vulnerability to iron-catalyzed reactive oxygen species generation. Experimental studies and gene expression analyses have identified ferroptosis-related pathways enriched in epileptic tissue, while human biomarker investigations demonstrate reduced glutathione levels and elevated lipid peroxidation products in patients with epilepsy. Although most therapeutic data derive from preclinical rodent models, pharmacological modulation of ferroptosis – via iron chelation or inhibition of lipid peroxidation – has shown seizure-reducing and neuroprotective effects. Importantly, ferroptosis likely operates alongside other regulated cell death pathways rather than acting as a singular mechanism. Shared features of iron accumulation and lipid peroxidation in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, further support a broader pathogenic relevance. Continued translational investigation is necessary to determine whether targeting ferroptosis may offer disease-modifying strategies in epilepsy.
- Open Access
- 22 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3872-3873
Molecular glue degraders versus PROTACs: a novel paradigm in targeted protein degradation
Many proteins that cause cancer are still out of reach for regular drugs because they do not have the right structure for small molecules to bind to. Targeted protein degradation (TPD) is a new way to do things. Instead of blocking these proteins, it takes over the cell’s own disposal system, the ubiquitin-proteasome system, to get rid of them completely. Two main strategies have emerged: molecular glue degraders, which are small compounds that help an E3 ligase find and tag a target protein, and PROteolysis TArgeting Chimeras (PROTACs), which are engineered bifunctional molecules that physically connect a target to a degradation pathway. Both have shown real promise in early clinical work. PROTACs that target Bruton’s tyrosine kinase have shown great response rates in B-cell cancers, and molecular glues that target Ikaros family proteins (IKZF1/3) are still helping people with blood cancers. But there are still problems. PROTACs have trouble dissolving and getting into the body through the mouth. The “hook effect” can make them less effective at higher doses, and both strategies rely heavily on a small number of E3 ligases. To make progress, we need to add more enzymes to our toolkit, design molecules better, and get better data from clinical trials. With cooperation from academia, industry, and regulators, TPD could significantly expand the druggable proteome and transform cancer treatment.
- 22 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3872-3873
Open AccessMolecular glue degraders versus PROTACs: a novel paradigm in targeted protein degradation
Many proteins that cause cancer are still out of reach for regular drugs because they do not have the right structure for small molecules to bind to. Targeted protein degradation (TPD) is a new way to do things. Instead of blocking these proteins, it takes over the cell’s own disposal system, the ubiquitin-proteasome system, to get rid of them completely. Two main strategies have emerged: molecular glue degraders, which are small compounds that help an E3 ligase find and tag a target protein, and PROteolysis TArgeting Chimeras (PROTACs), which are engineered bifunctional molecules that physically connect a target to a degradation pathway. Both have shown real promise in early clinical work. PROTACs that target Bruton’s tyrosine kinase have shown great response rates in B-cell cancers, and molecular glues that target Ikaros family proteins (IKZF1/3) are still helping people with blood cancers. But there are still problems. PROTACs have trouble dissolving and getting into the body through the mouth. The “hook effect” can make them less effective at higher doses, and both strategies rely heavily on a small number of E3 ligases. To make progress, we need to add more enzymes to our toolkit, design molecules better, and get better data from clinical trials. With cooperation from academia, industry, and regulators, TPD could significantly expand the druggable proteome and transform cancer treatment.
- Open Access
- 20 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (5) , 2990-2991
Copper-histidine therapy: a targeted metabolic intervention for Menkes disease
Menkes disease (MD) is a rare, X-linked recessive disorder of copper metabolism, characterized by progressive neurodegeneration, connective tissue abnormalities, and the distinctive phenotype of pili torti. The disease is caused by pathogenic variants in the ATP7A gene, which encodes a copper-transporting P-type ATPase essential for cellular copper efflux and delivery of copper to secreted cuproenzymes. Severe forms of MD typically present in early infancy and are associated with rapid neurological decline and death within the first 3 years of life. Currently, therapeutic options are limited, and outcomes are highly dependent on the timing of intervention. Copper-histidine represents a biologically rational intervention designed to bypass defective intestinal copper transport and restore systemic copper availability. Experimental and clinical observations suggest that early administration may partially correct copper deficiency, improve biochemical parameters, and, in selected cases, alter neurological outcomes and survival. This letter summarizes the pathophysiological basis of MD, the rationale for copper-histidine therapy, and the existing evidence supporting its potential role as a disease-modifying intervention when initiated early in life.
- 20 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (5) , 2990-2991
Open AccessCopper-histidine therapy: a targeted metabolic intervention for Menkes disease
Menkes disease (MD) is a rare, X-linked recessive disorder of copper metabolism, characterized by progressive neurodegeneration, connective tissue abnormalities, and the distinctive phenotype of pili torti. The disease is caused by pathogenic variants in the ATP7A gene, which encodes a copper-transporting P-type ATPase essential for cellular copper efflux and delivery of copper to secreted cuproenzymes. Severe forms of MD typically present in early infancy and are associated with rapid neurological decline and death within the first 3 years of life. Currently, therapeutic options are limited, and outcomes are highly dependent on the timing of intervention. Copper-histidine represents a biologically rational intervention designed to bypass defective intestinal copper transport and restore systemic copper availability. Experimental and clinical observations suggest that early administration may partially correct copper deficiency, improve biochemical parameters, and, in selected cases, alter neurological outcomes and survival. This letter summarizes the pathophysiological basis of MD, the rationale for copper-histidine therapy, and the existing evidence supporting its potential role as a disease-modifying intervention when initiated early in life.
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3861-3863
Next-generation antibody–drug conjugates in drug-resistant solid tumors: promise, toxicity, and the emerging challenge of acquired resistance
Drug-resistant solid tumors represent a major challenge in oncology, with resistance mechanisms, including efflux pump overexpression, apoptotic pathway alterations, and adaptive survival signaling, contributing to poor outcomes despite multimodal therapy. Conventional chemotherapy and first-generation antibody–drug conjugates (ADCs), such as ado-trastuzumab emtansine (T-DM1), were limited by non-specific cytotoxicity, heterogeneous drug–antibody ratios, linker instability, and insufficient bystander killing, yielding modest efficacy in heavily pretreated populations. Next-generation ADCs address these shortcomings through site-specific conjugation, advanced cleavable linkers, and novel payloads, such as topoisomerase I inhibitors, enabling robust bystander killing and circumvention of efflux-mediated resistance. Clinically, trastuzumab deruxtecan demonstrated meaningful progression-free survival benefit in HER2-low metastatic breast cancer, while enfortumab vedotin reduced mortality risk in platinum- and immunotherapy-refractory urothelial carcinoma, establishing ADC efficacy across solid tumor histologies. However, significant toxicity concerns persist. Trastuzumab deruxtecan carries a 15.4% incidence of interstitial lung disease, including fatal events, and sacituzumab govitecan is associated with grade 3 or higher neutropenia in approximately 51% of patients. Furthermore, next-generation ADCs are not resistance-proof, with antigen downregulation, payload efflux, and impaired internalization emerging as clinically relevant escape mechanisms. Biomarker-driven patient selection, rigorous toxicity monitoring, and prospective trials addressing resistance will be essential to realizing the full and durable potential of this drug class.
- 14 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3861-3863
Open AccessNext-generation antibody–drug conjugates in drug-resistant solid tumors: promise, toxicity, and the emerging challenge of acquired resistance
Drug-resistant solid tumors represent a major challenge in oncology, with resistance mechanisms, including efflux pump overexpression, apoptotic pathway alterations, and adaptive survival signaling, contributing to poor outcomes despite multimodal therapy. Conventional chemotherapy and first-generation antibody–drug conjugates (ADCs), such as ado-trastuzumab emtansine (T-DM1), were limited by non-specific cytotoxicity, heterogeneous drug–antibody ratios, linker instability, and insufficient bystander killing, yielding modest efficacy in heavily pretreated populations. Next-generation ADCs address these shortcomings through site-specific conjugation, advanced cleavable linkers, and novel payloads, such as topoisomerase I inhibitors, enabling robust bystander killing and circumvention of efflux-mediated resistance. Clinically, trastuzumab deruxtecan demonstrated meaningful progression-free survival benefit in HER2-low metastatic breast cancer, while enfortumab vedotin reduced mortality risk in platinum- and immunotherapy-refractory urothelial carcinoma, establishing ADC efficacy across solid tumor histologies. However, significant toxicity concerns persist. Trastuzumab deruxtecan carries a 15.4% incidence of interstitial lung disease, including fatal events, and sacituzumab govitecan is associated with grade 3 or higher neutropenia in approximately 51% of patients. Furthermore, next-generation ADCs are not resistance-proof, with antigen downregulation, payload efflux, and impaired internalization emerging as clinically relevant escape mechanisms. Biomarker-driven patient selection, rigorous toxicity monitoring, and prospective trials addressing resistance will be essential to realizing the full and durable potential of this drug class.
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3812-3814
Reconsidering immunotherapy resistance: the emerging role of the tumor microbiome in head and neck and lung cancers
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized treatment for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), yet resistance limits durable responses in many patients. Emerging evidence implicates the intratumoral microbiome – comprising bacteria, fungi, and viruses within tumor tissues – as a key modulator of tumor biology, immune infiltration, and ICI sensitivity, beyond traditional tumor-intrinsic and immune factors. In HNSCC, human papillomavirus (HPV)-negative tumors exhibit higher oncobacteria abundance than HPV-positive ones, with elevated levels linked to worse survival in HPV-positive oropharyngeal cases, suggesting an immunosuppressive tumor microenvironment that may influence ICI outcomes. In NSCLC, intratumoral taxa such as Fusobacterium nucleatum and Bacteroides fragilis promote progression and evasion via immune checkpoint modulation (PD-1/PD-L1), pro-inflammatory pathways (toll-like receptors and cytokines like interleukin-6/tumour necrosis factor-alpha), metabolic reprogramming (PI3K/AKT), and recruitment of suppressive cells (neutrophils and myeloid-derived suppressor cells). Pan-cancer studies show microbial enrichments and compositional shifts in responders versus non-responders to ICI, with metabolites (e.g., lactate and succinic acid) driving M2 macrophage polarization, T-cell suppression, and resistance. The gut–tumor axis further exacerbates refractoriness through systemic dysbiosis and immune alterations. Preclinical models indicate that targeted microbiome interventions – such as fecal microbiota transplantation, specific probiotics (e.g., Bifidobacterium spp. and Akkermansia muciniphila ), or selective antibiotics – can restore antitumor immunity, enhance ICI efficacy, and minimize broad dysbiosis risks. Integrating intratumoral microbial profiling into HNSCC and NSCLC clinical trials could refine patient stratification, uncover predictive biomarkers, and accelerate microbiome-directed adjunct therapies, advancing precision oncology and expanding immunotherapy benefits.
- 14 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3812-3814
Open AccessReconsidering immunotherapy resistance: the emerging role of the tumor microbiome in head and neck and lung cancers
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized treatment for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), yet resistance limits durable responses in many patients. Emerging evidence implicates the intratumoral microbiome – comprising bacteria, fungi, and viruses within tumor tissues – as a key modulator of tumor biology, immune infiltration, and ICI sensitivity, beyond traditional tumor-intrinsic and immune factors. In HNSCC, human papillomavirus (HPV)-negative tumors exhibit higher oncobacteria abundance than HPV-positive ones, with elevated levels linked to worse survival in HPV-positive oropharyngeal cases, suggesting an immunosuppressive tumor microenvironment that may influence ICI outcomes. In NSCLC, intratumoral taxa such as Fusobacterium nucleatum and Bacteroides fragilis promote progression and evasion via immune checkpoint modulation (PD-1/PD-L1), pro-inflammatory pathways (toll-like receptors and cytokines like interleukin-6/tumour necrosis factor-alpha), metabolic reprogramming (PI3K/AKT), and recruitment of suppressive cells (neutrophils and myeloid-derived suppressor cells). Pan-cancer studies show microbial enrichments and compositional shifts in responders versus non-responders to ICI, with metabolites (e.g., lactate and succinic acid) driving M2 macrophage polarization, T-cell suppression, and resistance. The gut–tumor axis further exacerbates refractoriness through systemic dysbiosis and immune alterations. Preclinical models indicate that targeted microbiome interventions – such as fecal microbiota transplantation, specific probiotics (e.g., Bifidobacterium spp. and Akkermansia muciniphila ), or selective antibiotics – can restore antitumor immunity, enhance ICI efficacy, and minimize broad dysbiosis risks. Integrating intratumoral microbial profiling into HNSCC and NSCLC clinical trials could refine patient stratification, uncover predictive biomarkers, and accelerate microbiome-directed adjunct therapies, advancing precision oncology and expanding immunotherapy benefits.
- Open Access
- 9 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2166-2167
Therapeutic advances in acute myeloid leukemia: from LSD1 blockade to PROTAC-based strategies
Acute myeloid leukemia (AML) is a fast-progressing blood cancer marked by immature myeloid cells and poor survival rates. Most AML subtypes resist standard treatments, especially in older adults, highlighting the need for new targeted therapies. A hallmark of AML is LSD1 overexpression, which blocks blood cell maturation. Though some LSD1 inhibitors can trigger differentiation, their use is limited by toxicity and incomplete target inhibition. PROTAC degraders like MS9117 offer a promising solution by eliminating LSD1. This halts leukemia growth, promotes robust cell differentiation, and restores sensitivity to agents like all-trans retinoic acid, benefits not seen with traditional inhibitors. PROTACs can also target previously undruggable proteins, such as transcription factors, potentially enabling lower doses and fewer side effects. Several PROTAC therapies are now in AML trials. LSD1-targeted degradation is promising, but further research is needed to confirm its safety, overcome resistance, and identify optimal drug combinations for AML treatment.
- 9 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 2166-2167
Open AccessTherapeutic advances in acute myeloid leukemia: from LSD1 blockade to PROTAC-based strategies
Acute myeloid leukemia (AML) is a fast-progressing blood cancer marked by immature myeloid cells and poor survival rates. Most AML subtypes resist standard treatments, especially in older adults, highlighting the need for new targeted therapies. A hallmark of AML is LSD1 overexpression, which blocks blood cell maturation. Though some LSD1 inhibitors can trigger differentiation, their use is limited by toxicity and incomplete target inhibition. PROTAC degraders like MS9117 offer a promising solution by eliminating LSD1. This halts leukemia growth, promotes robust cell differentiation, and restores sensitivity to agents like all-trans retinoic acid, benefits not seen with traditional inhibitors. PROTACs can also target previously undruggable proteins, such as transcription factors, potentially enabling lower doses and fewer side effects. Several PROTAC therapies are now in AML trials. LSD1-targeted degradation is promising, but further research is needed to confirm its safety, overcome resistance, and identify optimal drug combinations for AML treatment.